| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumo NCT02684071 | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | Phase 2 |
| Completed | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or R NCT02444546 | Mayo Clinic | Phase 1 |
| Completed | Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors NCT02271711 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervou NCT02255461 | Pediatric Brain Tumor Consortium | Phase 1 |
| Withdrawn | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors NCT02194452 | Sue O'Dorisio | N/A |
| Completed | Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma NCT01239316 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS T NCT01088763 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spi NCT01076530 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Cent NCT00994500 | National Cancer Institute (NCI) | Phase 1 |
| Completed | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors NCT00946335 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Trea NCT00822458 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagn NCT00638898 | City of Hope Medical Center | Phase 1 |
| Completed | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medul NCT00381797 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma NCT00363272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors NCT00326664 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, NCT00217412 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas NCT00101270 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors NCT00100880 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors NCT00095940 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors NCT00919750 | Children's Oncology Group | — |
| Completed | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors NCT00077454 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primit NCT00070525 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cilengitide in Treating Children With Refractory Primary Brain Tumors NCT00063973 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors NCT00052780 | National Cancer Institute (NCI) | Phase 1 |
| Completed | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas NCT00012181 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatmen NCT00005811 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Irinotecan in Treating Children With Refractory Solid Tumors NCT00004078 | Children's Oncology Group | Phase 2 |